Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of INS068 Injection New vs Old Formulations
NCT05336071Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin sudelidec in diabetes mellitus (DM) (2 arms), sponsored by Hengrui. Primary endpoints: Maximum observed serum concentration, Area under the plasma concentration versus time curve (AUC0-t) and 1 more. Started May 2022; status: completed.
02
Drugs
insulin sudelidec
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05336071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336071.